Targeting the myeloid microenvironment in neuroblastoma.

Autor: Stip MC; Center for Translational Immunology, University Medical Center Utrecht, 3584 CX, Utrecht, The Netherlands., Teeuwen L; Center for Translational Immunology, University Medical Center Utrecht, 3584 CX, Utrecht, The Netherlands., Dierselhuis MP; Princess Máxima Center for Pediatric Oncology, 3584 CS, Utrecht, The Netherlands., Leusen JHW; Center for Translational Immunology, University Medical Center Utrecht, 3584 CX, Utrecht, The Netherlands., Krijgsman D; Center for Translational Immunology, University Medical Center Utrecht, 3584 CX, Utrecht, The Netherlands. d.krijgsman-4@umcutrecht.nl.; Center for Molecular Medicine, University Medical Center Utrecht, 3584 CX, Utrecht, the Netherlands. d.krijgsman-4@umcutrecht.nl.

Publikováno v: Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2023 Dec 13; Vol. 42 (1), pp. 337. Date of Electronic Publication: 2023 Dec 13.

IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models.

Autor: Stip MC; Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands., Evers M; Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands., Nederend M; Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands., Chan C; Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands., Reiding KR; Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Biopharmaceutical Sciences, University of Utrecht, Utrecht, The Netherlands.; Netherlands Proteomics Center, Utrecht, The Netherlands., Damen MJ; Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Biopharmaceutical Sciences, University of Utrecht, Utrecht, The Netherlands., Heck AJR; Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Biopharmaceutical Sciences, University of Utrecht, Utrecht, The Netherlands.; Netherlands Proteomics Center, Utrecht, The Netherlands., Koustoulidou S; MIlabs, Utrecht, The Netherlands., Ramakers R; MIlabs, Utrecht, The Netherlands., Krijger GC; Radionuclide Pharmacy, UMC Utrecht, Utrecht, The Netherlands., de Roos R; Radionuclide Pharmacy, UMC Utrecht, Utrecht, The Netherlands., Souteyrand E; Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands., Cornel AM; Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Dierselhuis MP; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Jansen M; Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands., de Boer M; De Boer Biotech Consultancy B.V, Blaricum, The Netherlands., Valerius T; Section for Stem Cell Transplantation and Immunotherapy, Department of Medicine II, University Hospital Schleswig Holstein, Kiel, Germany., van Tetering G; Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands., Leusen JHW; Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands j.h.w.leusen@umcutrecht.nl., Meyer-Wentrup F; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2023 Jul; Vol. 11 (7).

hMRP8-ATTAC Mice: A New Model for Conditional and Reversible Neutrophil Ablation.

Autor: Duits DEM; Division of Tumor Biology & Immunology, Oncode Institute, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.; Department of Immunology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Salvagno C; Division of Tumor Biology & Immunology, Oncode Institute, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.; Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY 10065, USA.; Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10065, USA., Raeven EAM; Division of Tumor Biology & Immunology, Oncode Institute, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands., Vrijland K; Division of Tumor Biology & Immunology, Oncode Institute, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands., Stip MC; Division of Tumor Biology & Immunology, Oncode Institute, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.; Immunotherapy Laboratory, Laboratory for Translational Immunology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands., Hau CS; Division of Tumor Biology & Immunology, Oncode Institute, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands., Kaldenbach D; Division of Tumor Biology & Immunology, Oncode Institute, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands., de Visser KE; Division of Tumor Biology & Immunology, Oncode Institute, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.; Department of Immunology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.

Publikováno v: Cells [Cells] 2022 Jul 30; Vol. 11 (15). Date of Electronic Publication: 2022 Jul 30.

Mitochondrial ribosomal protein S18-2 is highly expressed in endometrial cancers along with free E2F1.

Autor: Mints M; Department of Women's and Children's Health (KBH), Karolinska Institutet, Stockholm, 17176, Sweden., Mushtaq M; Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, Stockholm, 17177, Sweden., Iurchenko N; R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, Kyiv, 03022, Ukraine., Kovalevska L; R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, Kyiv, 03022, Ukraine., Stip MC; Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, Stockholm, 17177, Sweden., Budnikova D; R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, Kyiv, 03022, Ukraine., Andersson S; Department of Women's and Children's Health (KBH), Karolinska Institutet, Stockholm, 17176, Sweden., Polischuk L; R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, Kyiv, 03022, Ukraine., Buchynska L; R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, Kyiv, 03022, Ukraine., Kashuba E; Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, Stockholm, 17177, Sweden.; R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, Kyiv, 03022, Ukraine.

Publikováno v: Oncotarget [Oncotarget] 2016 Apr 19; Vol. 7 (16), pp. 22150-8.